Carbimazole-induced Agranulocytosis
Medical and Clinical Case Reports · 31.12.2025 · 5 (4)
DOI: 10.33425/2768-6647.1073 ↗Kurz gefasst
Fachartikel in der Zeitschrift Medical and Clinical Case Reports, online erschienen am 31.12.2025. Verfasst von Hisham Abid Aldabbagh und 14 weiteren Autor:innen.
Abstract (Originalsprache)
This is a-46 years-old female was admitted in Qurayyat general hospital with Cardiomyopathy and Hyperthyroidism, was put on Carbimazole 60 mg orally daily.
Background
Hyperthyroidism four weeks back on Carbimazole 60 mg orally daily. Presentation: This patient presented with few days of palpitation and general fatigue, found have Cardiomyopathy, with severe neutropenia (Agranulocytosis), managed by cardiac team for Cardiomyopathy, with internal medicine team for her neutropenia. Carbimazole was stopped immediately. Started on Filgrastim a Granulocyte colony-stimulating factor (G-CSF) 300 mcg SC daily, with neutropenic antibiotic coverage and application of isolation precautions. But there was no response to Filgrastim initially. However, after 7 days of administering Filgrastim, WBC with neutrophil started to recover and increase in number, returned to normal range on day 9 of treatment, so Filgrastim was stopped. However, WBC and Neutrophil showed rebound increase in the next three days until reached 50.600/ cmm, and then returned again to normal range on day 13. Her cardiac condition stabilized on cardiac medication.
Conclusion
Carbimazole is used to treat hyperthyroidism; however, Agranulocytosis is a rare but potentially life-threatening side effect occurs during the first few months of treatment. If patients develop symptoms such as fever or a sore throat, blood tests should be performed immediately, and Carbimazole should be discontinued if Agranulocytosis is suspected.
Zitieren
APA
Aldabbagh, H. A., Ajina, M. A., Elbagi, M. A., Alkhaldi, E. H., AlAnazi, H. M., KC, S., Alatawi, L. I., Bello, A. T. L., ElImam, A. H., CU, O. C., Alajaji, A. H., Alsharari, A. H. J., AA, N., Castro, H. G., & Aldabbagh, A. H. (2025). Carbimazole-induced Agranulocytosis. Medical and Clinical Case Reports, 5(4). https://doi.org/10.33425/2768-6647.1073
Vancouver
Aldabbagh HA, Ajina MA, Elbagi MA, Alkhaldi EH, AlAnazi HM, KC S, et al. Carbimazole-induced Agranulocytosis. Medical and Clinical Case Reports. 2025;5(4). doi:10.33425/2768-6647.1073
BibTeX
@article{Aldabbagh2025,
author = {Aldabbagh, Hisham Abid and Ajina, Manal Abdulrahman and Elbagi, Mohammed Abd and Alkhaldi, Eid Hmoud and AlAnazi, Hanan Mansour and KC, Sajedul and Alatawi, Latifah Ibrahim and Bello, Amina Titilayo Lawal and ElImam, Adil Hassan and CU, Onyinye Chieme and Alajaji, Abdullah Hamad and Alsharari, Awad Hamdan J and AA, Nasaym and Castro, Haidelyn Gumatay and Aldabbagh, Adbalrhman Hisham},
title = {Carbimazole-induced Agranulocytosis},
journal = {Medical and Clinical Case Reports},
year = {2025},
volume = {5},
number = {4},
doi = {10.33425/2768-6647.1073}
}
EUVIMED